ARGX-119 may aid muscle strength in some people with MuSK MG
Treatment with ARGX-119, an experimental therapy being developed by Argenx, led to improvements in muscle strength and survival…
Marisa Horak joined Bionews in 2018 right after she completed her master’s degree in cellular and molecular pathology. She has dedicated her career to making scientific and medical information more accessible to people affected by rare and chronic disorders.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Treatment with ARGX-119, an experimental therapy being developed by Argenx, led to improvements in muscle strength and survival…
Throughout 2024, the team at Myasthenia Gravis News has brought you the latest updates on research advances and treatment options…
People with myasthenia gravis (MG) who experience exacerbations tend to require longer and more frequent hospital stays, according to…
Cartesian Therapeutics is planning to launch a pivotal, Phase 3 clinical trial of its experimental cell therapy…
A machine learning model taking into account markers of inflammation and clinical data may accurately predict whether people with…
Treatment with Soliris (eculizumab) was effective for managing myasthenic crisis in four people with myasthenia gravis (MG) at…
People with generalized myasthenia gravis (gMG) with many hospital visits before diagnosis or hard-to-manage disease symptoms at the…
The case of a pregnant woman with myasthenia gravis (MG) who saw her disease worsen and who developed hydramnios…
A traditional Chinese medicine practice that combines acupuncture and moxibustion, given along with standard treatments, may ease symptoms for people…
Vyvgart (efgartigimod) eased symptoms of generalized myasthenia gravis (gMG) for some patients in Japan and the therapy’s effects…
Get regular updates to your inbox.